Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2023 | COVID-19 and the risk of demyelinating diseases

There is plenty of evidence to support the association between viral infections and the development of demyelinating diseases. Lorna Galleguillos, MD, Clínica Alemana de Santiago, Vitacura, Chile, discusses the possibility of SARS-CoV-2 infection triggering the development of multiple sclerosis (MS) and other demyelinating diseases. There are some case reports of peripheral nervous system involvement following SARS-CoV-2 infection, as well as the development of demyelinating diseases in some patients. Following COVID-19 vaccination, demyelinating complications of the central nervous system, such as acute disseminated encephalomyelitis (ADEM), have been reported. However, there is insufficient evidence to support that COVID-19 infection or vaccines trigger MS or exacerbate MS symptoms, and further studies are needed. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.